hit counter

Aripiprazole Oculogyric Crisis in Tourette Tics: 2 Cases at 20-30 mg

MHD featured image for aripiprazole-related oculogyric crisis in Tourette tic treatment.

A 2026 Neurological Sciences brief communication added 2 Tourette syndrome cases of aripiprazole-related oculogyric crisis — sustained, involuntary upward eye deviation from extraocular-muscle dystonia — after titration to 20 mg and 30 mg daily, with remission after dose reduction.1 Research Highlights 2 new Tourette cases: Cavanna et al. reported oculogyric crisis in females aged 16 …

Read more

Eutylone Inhibits CYP2D6 Like MDMA: Polydrug Interaction Risk

MHD featured image for eutylone, CYP2D6 inhibition, and polydrug interaction risk.

A 2026 cross-species metabolism study found that eutylone, a synthetic cathinone stimulant sometimes sold as a “bath salt” or MDMA-like drug, inactivated CYP2D6 with Ki = 4.2 μM, kinact = 0.069 min-1, and inactivation efficiency = 1.64 x 10-2 min-1 μM-1 — a range the researchers described as comparable to MDMA. Research Highlights CYP2D6 was …

Read more

Risperidone in Dementia Raised Stroke-Related Events 4.11x by Week 4

MHD featured image for risperidone adverse events in dementia.

A 2026 individual participant data meta-analysis of 1,721 dementia trial participants linked risperidone to cerebrovascular adverse events, HR 4.11 (95% CI 1.77 to 9.51), and major cardiovascular adverse events, HR 2.00 (95% CI 1.23 to 3.26).1 The timing signal is the practical warning: median first cerebrovascular event appeared at 4.3 weeks, and median first major …

Read more

SSRI Pharmacogenomic Testing: CYP2D6, CYP2C19, Remission

MHD featured image for SSRI Pharmacogenomic Testing: CYP2D6, CYP2C19, Remission.

A 2026 methylome-wide association study by Shen et al. found 48 CpG methylation sites tied to the quadratic CYP2C19 metabolizer-status term in 18,396 Generation Scotland participants, with 19 sites showing non-linear patterns and targeted replication in 1,238 older adults.1 That supports CYP2C19 as real biology beneath SSRI pharmacogenomics, but it does not prove universal antidepressant …

Read more

Esketamine Can Trigger Trauma Re-Experiencing in PTSD

Photoreal illustration of a patient receiving nasal spray with overlay of trauma memory imagery, conveying esketamine + PTSD interaction.

A 2026 retrospective case series of 22 adults with treatment-resistant depression and comorbid PTSD found that trauma re-experiencing during intranasal esketamine disappeared over later sessions in 72.7% of patients, while 27.3% stopped esketamine because the flashbacks persisted.1 Research Highlights Flashbacks usually faded, but not always: In 16 of 22 patients (72.7%), esketamine-related trauma re-experiencing disappeared …

Read more

Dexamethasone Disrupts Mouse Sleep Through Orexin Hyperarousal

Photoreal illustration of a steroid pill bottle with overlay of disrupted sleep architecture, conveying glucocorticoid-induced insomnia mechanism.

A 2026 male-mouse study found that 30 mg/kg dexamethasone for 5 days increased light-phase wakefulness (t13 = 4.122, p = 0.0012), decreased NREM sleep (t13 = 4.412, p = 0.0007), and amplified orexin-neuron activity during NREM-to-wake transitions (F1,9 = 6.941, p = 0.0272). The result points to orexin-linked hyperarousal as a testable explanation for steroid-induced …

Read more

Cannabis After Pregnancy Did Not Increase Hypertension Risk in nuMoM2b

Photoreal illustration of a postpartum woman with stethoscope and cannabis imagery, conveying cardiovascular implications of postpartum cannabis use.

A 2026 nuMoM2b Heart Health Study analysis tested whether urine-confirmed cannabis exposure 2–7 years after a first pregnancy predicted incident stage II hypertension; it did not: adjusted odds ratio (AOR) 1.05, 95% CI 0.63–1.76, with 216 of 4,079 participants developing hypertension.1 Research Highlights The headline result was null: cannabis exposure at the 2–7 year postpartum …

Read more